Trial Condition(s):

Chronic Bronchitis

SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe Acute Exacerbations of Chronic Bronchitis (AECB) (SYMPROVE III)

Bayer Identifier:

12629

ClinicalTrials.gov Identifier:

NCT00879008

EudraCT Number:

Not Available

Study Completed

Trial Purpose

In this study data of patients with moderate or severe acute exacerbations of chronic bronchitis (AECB) were collected. There were two different cohorts which were compared (Moxifloxacin and other antibiotics) concerning effectiveness and tolerance. It was a prospective study which was accomplished in 100 ambulatory practice offices.

Inclusion Criteria
- Acute exacerbation of chronic bronchitis from Anthonisen type I or II 
 - FEV1 of < 50 % 
 - Patient must be ensured in the statutory health insurance 
 - Further contraindications of the prescribed pharmaceutical products must be considered
Exclusion Criteria
- Patients who change from one cohort to the other

Trial Summary

Enrollment Goal
345
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Avelox (Moxifloxacin hydrochloride, BAY12-8039)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Germany

Status
Completed
 

Trial Design